22:04 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting GIP receptor could help treat MI. In a mouse model of MI, cardiomyocyte-specific knockout of GIP receptor increased survival and decreased left ventricular remodeling and scar formation at...
22:58 , Oct 6, 2017 |  BioCentury  |  Emerging Company Profile

Metabolic contrarian

Antag Therapeutics ApS is going against the grain, blocking rather than boosting the effects of glucose-dependent insulinotropic polypeptide to treat obesity and diabetes. While several other companies are developing agonists to enhance the peptide’s glucose-regulating activity,...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
20:42 , Jun 28, 2017 |  BC Extra  |  Financial News

Novo Seeds invests €2.7M in Antag

Metabolic start-up Antag Therapeutics ApS (Copenhagen, Denmark) said it has received a €2.7 million ($3 million) investment from Novo Seeds, the early stage investment arm of Novo Holdings A/S (Hellerup, Denmark). Antag is developing peptide therapeutics...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

Zealand Pharma preclinical data

In a mouse model of obesity, subcutaneous ZP-DI-70 every 3 days for 18 days reduced body weight by 4% at the 1 nmol/kg dose and by 13% at the 3 nmol/kg dose. In diabetic mice,...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glucose-dependent insulinotropic polypeptide (GIP) receptor; glucagon-like peptide-1 receptor (GLP-1R; GLP1R); glucagon receptor (GCGR)

Endocrine/metabolic disease INDICATION: Obesity; diabetes Mouse studies suggest a monomeric peptide agonist of GIP receptor, GLP1R and GCGR could help treat obesity and diabetes. In a mouse model of diet-induced obesity, the triple agonist decreased body weight...
08:00 , Dec 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity; diabetes Glucagon-like peptide-1 receptor (GLP-1R; GLP1R); glucagon receptor (GCGR); glucose-dependent insulinotropic polypeptide receptor (GIP receptor) ...
07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms mAb antagonists against glucose-dependent insulinotropic polypeptide receptor (GIPR) mAb antagonists against GIPR could be useful as tools to develop...
08:00 , Feb 25, 2013 |  BioCentury  |  Emerging Company Profile

Longevity: Internal Improvements

A handful of companies are using non-natural amino acids to improve the pharmacokinetic and metabolic profiles of peptides and proteins, but such modifications often alter the surface of the molecule, which can affect its binding...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

RG7685: Development discontinued

In its 3Q12 earnings, Roche said that it discontinued development of RG7685, which was in Phase I testing for Type II diabetes. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: RG7685 (formerly MAR701)   Business: Endocrine/Metabolic   Molecular target:...